The First CE-Marked Antibiotic-Eluting Bone Substitute


Osteomyelitis (bone infection) is a 1.7 billion-dollar (US) market. Standard treatment currently consists of long-term courses of antibiotics, repeated surgical operations (due to constant failure), and possible amputation. The increasing incidence of prosthetic infections, as well as diabetic ulcers, war and sports injuries, and growing antibiotic resistance, are all contributing to a rise in osteomyelitis rates. Bone infections are often very hard to manage and may require two-stage operations. “Our challenge was to develop a new generation of bone substitute that helps maintain bone integrity and growth while also actively treating infections.


About Peter Coffaro 1430 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the medical device industry. As a District Sales Manager for Stryker Orthopaedics, Peter was responsible for managing and directing a regional sales force to achieve sales and profit goals within the Rocky Mountain region. Previously, he was the Director of Sales & Marketing for Amp Orthopedics. In this role, Peter was responsible for planning, developing, and leading all sales and marketing initiatives. Peter is a former orthopedic distributor in the Pacific Northwest. He has also worked with DePuy Orthopaedics as well as Zimmer, and held positions in sales, sales training, and sales management. Peter has an extensive background in organizational development, business development, sales management, negotiating and P&L management. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.